Eva Sahakian, Ph.D.
Affiliations: | 2010 | Loma Linda University, Loma Linda, United States |
Area:
Microbiology Biology, Genetics, Molecular BiologyGoogle:
"Eva Sahakian"Parents
Sign in to add mentor| Carlos A. Casiano | grad student | 2009 | Loma Linda University | |
| Michael B. Lilly | grad student | 2010 | Loma Linda University | |
| (Regulation of PIM1 under hypoxia in prostate cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gamal W, Sahakian E, Pinilla-Ibarz J. (2022) The role of Th17 cells in chronic lymphocytic leukemia: friend or foe? Blood Advances |
| Maharaj K, Uriepero A, Sahakian E, et al. (2022) Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Frontiers in Immunology. 13: 943354 |
| Mostofa A, Distler A, Meads MB, et al. (2021) Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. Jci Insight |
| Chen J, Cheng F, Sahakian E, et al. (2021) HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. Journal of Leukocyte Biology. 109: 891-900 |
| Maharaj K, Powers JJ, Mediavilla-Varela M, et al. (2020) HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology. 11: 590072 |
| Maharaj K, Powers JJ, Achille A, et al. (2020) The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances. 4: 3072-3084 |
| Yue L, Sharma V, Horvat NP, et al. (2019) HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood |
| Knox T, Sahakian E, Banik D, et al. (2019) Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 9: 14824 |
| Knox T, Sahakian E, Banik D, et al. (2019) Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 9: 6136 |
| Sharma V, Yue L, Horvat NP, et al. (2019) Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474 |